Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 31, 2023

Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial
JAMA Oncol 2023 Dec 14;[EPub Ahead of Print], KS Tewari, N Colombo, BJ Monk, C Dubot, MV Cáceres, K Hasegawa, R Shapira-Frommer, P Salman, E Yañez, M Gümüs, M Olivera Hurtado de Mendoza, V Samouëlian, V Castonguay, A Arkhipov, C Tekin, K Li, S Toker, SM Keefe, D Lorusso

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading